Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05115305 · ClinicalTrials.gov registry record

Prodigy, a Level 2 Sleep Study Device, Validation Study

A clinical trial of Sleep Apnea, sponsored by Cerebra Medical.

Completed
Registry status
84
Enrollment target
2
Study locations

NCT05115305: Completed study of Sleep Apnea, sponsored by Cerebra Medical.

NCT05115305 is a study of Sleep Apnea that has completed, run by Cerebra Medical. The registered enrollment target is 84 participants, below the 2,987-participant average among 36 other Sleep Apnea trials with a reported enrollment target (97% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05115305, a study of Sleep Apnea, has completed, sponsored by Cerebra Medical.

COMPLETED
Registry status
84 participants
Enrollment target
2
Study locations

Study Summary

The Prodigy system, developed by Cerebra Medical Ltd, allows for the generation of the same information in the home that is currently only obtained in in-laboratory studies. The objective of the current study is to demonstrate that the signals obtained by this comprehensive, portable system are comparable to those obtained in in-laboratory studies.

Primary Outcome

To compare Level 1 and Level 2 sleep tests on TST

Conditions Studied

Study Locations (2)

New York

  • St Charles Sleep Disorders Center - Port Jefferson

Ontario

  • Hamilton Sleep Disorders Clinic - Hamilton

Trial Details

FieldValue
Enrollment Target 84 participants
Start Date 2022-01-14
Est. Completion 2022-04-09
Cerebra Medical

1 total trials

What the finished NCT05115305 record still lists

NCT05115305 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 84 participants, a relatively small participant target, below the 2,987-participant average among 36 other Sleep Apnea trials with a reported enrollment target (97% lower).

The record links to 1 condition, with Sleep Apnea appearing as the primary indexed condition, and to 0 interventions.

NCT05115305 reports a single indexed study location in New York, Ontario.

Frequently Asked Questions

What is clinical trial NCT05115305 about?

NCT05115305 is a clinical study titled "Prodigy, a Level 2 Sleep Study Device, Validation Study". The Prodigy system, developed by Cerebra Medical Ltd, allows for the generation of the same information in the home that is currently only obtained in in-laboratory studies. The objective of the current study is to demonstrate that the signals obtained by this comprehensive, portable system are com...

What is the current status of trial NCT05115305?

This trial is currently completed. The enrollment target is 84 participants. The study started on 2022-01-14. Estimated completion is 2022-04-09.

What conditions does trial NCT05115305 study?

This clinical trial studies the following conditions: Sleep Apnea.

Who is sponsoring clinical trial NCT05115305?

This trial is sponsored by Cerebra Medical, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05115305 being conducted?

This trial has 2 study locations across New York, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Sleep Apnea

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05115305's enrollment target sits among peer trials

84 21st of 36 higher than 16 of 36 other Sleep Apnea trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Sleep Apnea trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02391519 · 84 participants

    Effects of High Altitude on AMPK Activation

  • NCT03838536 · 84 participants · NA

    Synergistic Activity of Human Milk Nutrients and Infant Cognition

  • NCT03884075 · 84 participants · Phase 2

    Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)

  • NCT03894917 · 84 participants

    Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05115305, the US trial registry maintained by the National Library of Medicine. NCT05115305 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.